[go: up one dir, main page]

AR067562A1 - Compuestos heterociclicos inhibidores de kinasa - Google Patents

Compuestos heterociclicos inhibidores de kinasa

Info

Publication number
AR067562A1
AR067562A1 ARP080103052A ARP080103052A AR067562A1 AR 067562 A1 AR067562 A1 AR 067562A1 AR P080103052 A ARP080103052 A AR P080103052A AR P080103052 A ARP080103052 A AR P080103052A AR 067562 A1 AR067562 A1 AR 067562A1
Authority
AR
Argentina
Prior art keywords
substituted
amino
aryl
hetero
aryloxy
Prior art date
Application number
ARP080103052A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38800784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR067562(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR067562A1 publication Critical patent/AR067562A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula (A): en donde: el anillo AD es un anillo heterocíclico aromático 5,6-bicíclico, en donde A es un anillo heterocíclico aromático de 5 miembros que contiene uno o mas átomos de O, S y N del anillo fusionado con el anillo D, el cual es un anillo de fenilo o un anillo heterocíclico aromático de 6 miembros que contiene uno, dos o tres átomos de nitrogeno del anillo, en donde el anillo AD esta sustituido por R2, R3, R4, y R5; E es un arilo de 6 a 10 átomos de carbono, un hetero-arilo de 5 a 10 miembros, o halogeno, en donde los anillos están opcionalmente sustituidos por R6, R7 y R8; Q es O o S; R1 se selecciona a partir del grupo que consiste en hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido alcoxilo, alcoxilo sustituido amino, amino sustituido, arilo, arilo sustituido, hetero-arilo, hetero-arilo sustituido, heterociclilo, cicloalquilo, cicloalquilo sustituido, heterociclilo sustituido, ariloxilo, ariloxilo sustituido, hetero-ariloxilo, hetero-ariloxilo sustituido, heterocicliloxilo, heterocicliloxilo sustituido, cicloalquiloxilo, cicloalquiloxilo sustituido, y alquil-amino; R2 Y R3 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, alcoxilo, alcoxilo sustituido, arilo, arilo sustituido, hetero-arilo, hetero-arilo sustituido, heterociclilo, cicloalquilo, cicloalquilo sustituido, heterociclilo sustituido, ariloxilo, ariloxilo sustituido, hetero-ariloxilo, hetero-ariloxilo sustituido, heterocicliloxilo, heterocicliloxilo sustituido, cicloalquiloxilo, cicloalquiloxilo sustituido, acilo, acilamino, aciloxilo, amino, amino sustituido, amino-carbonilo, amino-tiocarbonilo, amino-carbonil-amino, amino-tiocarbonil-amino, amino-carboniloxilo, amino-sulfonilo, amino-sulfoniloxilo, amino-sulfonil-amino, amidino, carboxilo, carboxil-éster, (carboxil-éster)-amino, (carboxil-éster)-oxilo, ciano, halogeno, hidroxilo, nitro, SO3H, sulfonilo, sulfonilo sustituido, sulfoniloxilo, tioacilo, tiol, tioalquilo, y tioalquilo sustituido; R4 y R5 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, halogeno, ciano, nitro, amino, amino sustituido, alcoxilo, alcoxilo sustituido, alquilo, y alquilo sustituido; R6 se selecciona a partir del grupo que consiste en hidrogeno, halogeno, ciano, nitro, alcoxilo, alcoxilo sustituido, alquilo, y alquilo sustituido; y R7 y R8 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, alcoxilo, alcoxilo sustituido, arilo, arilo sustituido, hetero-arilo, hetero-arilo sustituido, heterociclilo, cicloalquilo, cicloalquilo sustituido, heterociclilo sustituido, ariloxilo, ariloxilo sustituido, hetero-ariloxilo, hetero-ariloxilo sustituido, heterocicliloxilo, heterocicliloxilo sustituido, cicloalquiloxilo, cicloalquiloxilo sustituido, acilo, aciloxilo, amino-carbonilo, amino-tiocarbonilo, amino-tiocarbonil-amino, amino-carboniloxilo, amino-sulfonilo, amino-sulfoniloxilo, amino-sulfonil-amino, amidino, carboxilo, carboxil-éster, (carboxil-éster)-oxilo, ciano, halogeno, hidroxilo, nitro, SO3H, sulfonilo, sulfonilo sustituido, sulfoniloxilo, tioacilo, tiol, tioalquilo, y tioalquilo sustituido; o R7 y R8 junto con los átomos del anillo con los que están unidos, forman un grupo carbocíclico o heterocíclico de 5 a 8 miembros. Compuestos inhibidores de cinasa de fosíatidil-inositol (Pl)-3, sus sales farmacéuticamente aceptables, y pro-fármacos de los mismos; composiciones de los nuevos compuestos, ya sea solos o bien en combinacion con cuando menos un agente terapéutico adicional, con un vehículo farmacéuticamente aceptable y utilizacion de los compuestos, ya sea solos o bien en combinacion con cuando menos un agente terapéutico adicional, en la profilaxis o el tratamiento de enfermedades proliferativas caracterizadas por la actividad anormal de los factores de crecimiento, las cinasas de proteína serina/treonina, y las cinasas de fosfolípidos.
ARP080103052A 2007-07-18 2008-07-16 Compuestos heterociclicos inhibidores de kinasa AR067562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07112688 2007-07-18

Publications (1)

Publication Number Publication Date
AR067562A1 true AR067562A1 (es) 2009-10-14

Family

ID=38800784

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103052A AR067562A1 (es) 2007-07-18 2008-07-16 Compuestos heterociclicos inhibidores de kinasa

Country Status (15)

Country Link
US (1) US8053574B2 (es)
EP (1) EP2178868A1 (es)
JP (1) JP2010533680A (es)
KR (1) KR20100049073A (es)
CN (1) CN101801966A (es)
AR (1) AR067562A1 (es)
AU (1) AU2008277628B2 (es)
BR (1) BRPI0813831A2 (es)
CA (1) CA2693232A1 (es)
CL (1) CL2008002097A1 (es)
EA (1) EA201000130A1 (es)
MX (1) MX2010000716A (es)
PE (1) PE20090492A1 (es)
TW (1) TW200908969A (es)
WO (1) WO2009010530A1 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US8883820B2 (en) 2006-08-30 2014-11-11 Cellzome Ltd. Triazole derivatives as kinase inhibitors
ES2401557T3 (es) 2007-08-02 2013-04-22 Amgen, Inc Moduladores de Pl3 cinasas y métodos de uso
WO2009068482A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
JP5520831B2 (ja) * 2007-12-19 2014-06-11 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
EP2283013A1 (en) * 2008-04-16 2011-02-16 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
EP2444403A1 (en) 2008-04-18 2012-04-25 Shionogi Co., Ltd. Heterocyclic compound having inhibitory activity on PI3K
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010186A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
ES2663536T3 (es) 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agentes que se unen a receptores frizzled y usos de los mismos
WO2010074089A1 (ja) 2008-12-24 2010-07-01 第一三共株式会社 インダニル化合物
BRPI0923654A2 (pt) 2008-12-24 2018-10-16 Daiichi Sankyo Company, Limited composto, uso de um composto, e , composição farmacêutica.
WO2010092015A1 (en) * 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
JP2012521354A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
WO2010125799A1 (ja) 2009-04-27 2010-11-04 塩野義製薬株式会社 Pi3k阻害活性を有するウレア誘導体
EP2432782A1 (en) 2009-05-20 2012-03-28 Cellzome Ag Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins
US8501936B2 (en) 2009-06-05 2013-08-06 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
EP2448946B1 (en) * 2009-07-02 2013-07-24 Novartis AG 2-carboxamide cycloamino ureas useful as pi3k inhibitors
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2576544A4 (en) * 2010-06-01 2013-09-11 Angion Biomedica Corp INHIBITORS OF CYTOCHROMES P450 AND USES THEREOF
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
PL2699575T3 (pl) 2011-04-21 2015-08-31 Bayer Ip Gmbh Triazolopirydyny
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US20150132301A1 (en) * 2011-12-09 2015-05-14 Oncomed Pharmaceuticals, Inc. Combination Therapy for Treatment of Cancer
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
AP3778A (en) 2012-07-10 2016-08-31 Bayer Pharma AG Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
CN104870017B (zh) 2012-11-08 2020-08-14 理森制药股份公司 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
LT3008062T (lt) 2013-06-11 2017-06-12 Bayer Pharma Aktiengesellschaft Pakeistųjų triazolpiridinų provaistų dariniai
WO2015039333A1 (en) * 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
SG10201806846RA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9598424B2 (en) 2014-03-06 2017-03-21 Takeda Pharmaceutical Company Limited Heteroarylamide inhibitors of TBK1
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
PH12017501817B1 (en) 2015-04-03 2023-06-16 Incyte Holdings Corp Heterocyclic compounds as lsd1 inhibitors
TWI765860B (zh) 2015-08-12 2022-06-01 美商英塞特公司 Lsd1抑制劑之鹽
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
BR112019010511A2 (pt) 2016-11-23 2019-09-17 Bayer Ag derivados de heterociclo bicíclico fundido como pesticidas
MA46888A (fr) * 2016-11-28 2021-06-02 Bristol Myers Squibb Co Inhibiteurs de gsk-3
CA3078173A1 (en) 2017-10-02 2019-04-11 1ST Biotherapeutics, Inc. Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
KR20200139153A (ko) 2018-02-27 2020-12-11 인사이트 코포레이션 A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
CA3100731A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11098044B2 (en) 2019-02-22 2021-08-24 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
WO2020178795A1 (en) * 2019-03-07 2020-09-10 1ST Biotherapeutics, Inc. [ 18f]-labeled benzothiazole derivative as pet radiotracer
US10385046B1 (en) 2019-03-19 2019-08-20 1ST Biotherapeutics, Inc. Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders
CN111116580B (zh) * 2019-12-27 2022-08-23 上海应用技术大学 一种尼麦角林的改进制备方法
KR20240168991A (ko) * 2022-03-25 2024-12-02 주식회사 퍼스트바이오테라퓨틱스 조혈 전구체 키나제 1(hpk1) 억제제로서의 인다졸 및 이를 사용하는 방법
CN118239953A (zh) * 2022-12-23 2024-06-25 中国科学院合肥物质科学研究院 用于治疗PI3Kγ介导的疾病的化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0261459A3 (de) 1986-09-09 1988-05-11 Nihon Tokushu Noyaku Seizo K.K. Neue N-Benzothiazolylamide
SK286450B6 (sk) 1999-10-08 2008-10-07 Grnenthal Gmbh Bicyklické imidazo-3-yl-amíny, spôsob ich výroby,ich použitie a liečivá obsahujúce tieto látky
HUP0300359A2 (hu) * 2000-02-07 2003-06-28 Abbott Gmbh & Co. Kg. 2-Benzotiazolil-karbamid-származékok és protein kináz inhibitorként történő felhasználásuk és ezeket tartalmazó gyógyszerkészítmények
BRPI0507653A (pt) 2004-03-19 2007-07-10 Warner Lambert Co derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso
JP2008500284A (ja) 2004-05-12 2008-01-10 ブリストル−マイヤーズ　スクイブ　カンパニー 血栓症の治療に有用なｐ２ｙ１レセプターのウレアアンタゴニスト
US7636348B2 (en) 2004-06-30 2009-12-22 Bettis Sonny R Distributed IP architecture for telecommunications system with video mail
MX2007004179A (es) * 2004-10-07 2007-06-07 Warner Lambert Co Derivados de triazolpiridina como agentes antibacterianos.
US7576090B2 (en) * 2004-12-27 2009-08-18 4Sc Ag Benzazole analogues and uses thereof

Also Published As

Publication number Publication date
CL2008002097A1 (es) 2009-02-20
AU2008277628A1 (en) 2009-01-22
US8053574B2 (en) 2011-11-08
US20100197682A1 (en) 2010-08-05
MX2010000716A (es) 2010-03-26
JP2010533680A (ja) 2010-10-28
TW200908969A (en) 2009-03-01
CA2693232A1 (en) 2009-01-22
CN101801966A (zh) 2010-08-11
AU2008277628B2 (en) 2012-03-15
WO2009010530A1 (en) 2009-01-22
EA201000130A1 (ru) 2010-08-30
KR20100049073A (ko) 2010-05-11
EP2178868A1 (en) 2010-04-28
PE20090492A1 (es) 2009-05-27
BRPI0813831A2 (pt) 2015-01-06

Similar Documents

Publication Publication Date Title
AR067562A1 (es) Compuestos heterociclicos inhibidores de kinasa
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR074002A1 (es) Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir)
PE20191744A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
AR088760A1 (es) Derivados de pirrolopirimidina y purina
AR059087A1 (es) Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas.
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
CR20140216A (es) 5,7-imidazo[1,2-c]pirimidinas sustituidas
AR066214A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas
NI201000109A (es) Derivados bis-(sulfonilamino) para uso en terapia.
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
AR072791A1 (es) DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER.
AR066583A1 (es) Derivados de 3,3-espiroindolinona
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
AR062745A1 (es) 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
ES2577382T3 (es) Nuevos derivados de tienopirimidina, procedimientos para su preparación, y sus usos terapéuticos
AR066659A1 (es) Derivados de espiroindolinona
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич

Legal Events

Date Code Title Description
FA Abandonment or withdrawal